These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 415674

  • 1. Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy.
    Leonard JM, McGee ZA, Alford RH.
    Arch Intern Med; 1978 Feb; 138(2):201-5. PubMed ID: 415674
    [Abstract] [Full Text] [Related]

  • 2. [Amikacin in the treatment of hospital infections of the urinary tract caused by gram-negative bacilli resistant to gentamicin. Microbiological and clinical aspects].
    Romoli E, Di Leonardo F, Giordano G, De Felice M, Cerquetti F, Vonmoos A.
    Minerva Urol; 1981 Feb; 33(2):85-90. PubMed ID: 7322100
    [No Abstract] [Full Text] [Related]

  • 3. Amikacin therapy of gram-negative bacteremia and meningitis. Treatment in diseases due to multiple resistant bacilli.
    Sklaver AR, Greenman RL, Hoffman TA.
    Arch Intern Med; 1978 May; 138(5):713-6. PubMed ID: 348135
    [Abstract] [Full Text] [Related]

  • 4. Clinical efficacy of a synergistic combination of cefotaxime and amikacin against multiresistant Pseudomonas and Serratia infections.
    Maslow MJ, Simberkoff MS, Rahal JJ.
    J Antimicrob Chemother; 1985 Aug; 16(2):227-34. PubMed ID: 3934125
    [Abstract] [Full Text] [Related]

  • 5. [Clinico-bacteriological study of 20 Serratia marcescens infections treated with amikacin].
    Pérez González F, Prendes Peláez P, Meana Fonseca JL, Martín Alvarez R.
    Rev Clin Esp; 1985 Aug; 161(5-6):327-34. PubMed ID: 7027369
    [No Abstract] [Full Text] [Related]

  • 6. Amikacin therapy. Use against infections caused by gentamicin- and tobramycin-resistant organisms.
    Yu VL, Rhame FS, Pesanti EL, Axline SG.
    JAMA; 1977 Aug 29; 238(9):943-7. PubMed ID: 328950
    [Abstract] [Full Text] [Related]

  • 7. Amikacin therapy for serious gram-negative infection.
    Pollock AA, Berger SA, Richmond AS, Simberkoff MS, Rahal JJ.
    JAMA; 1977 Feb 07; 237(6):562-4. PubMed ID: 576282
    [Abstract] [Full Text] [Related]

  • 8. Use of Amikacin in a hospital for children: microbiological and clinical studies.
    Marget W, Reindke B, Versmold H.
    J Infect Dis; 1976 Nov 07; 134 SUPPL():S412-9. PubMed ID: 825592
    [Abstract] [Full Text] [Related]

  • 9. Amikacin therapy of patients with multiply antibiotic-resistant Serratia marcescens infections: development of increasing resistance during therapy.
    Craven PC, Jorgensen JH, Kaspar RL, Drutz DJ.
    Am J Med; 1977 Jun 07; 62(6):902-10. PubMed ID: 326046
    [Abstract] [Full Text] [Related]

  • 10. Controlled comparison of amikacin and gentamicin.
    Smith CR, Baughman KL, Edwards CQ, Rogers JF, Lietman PS.
    N Engl J Med; 1977 Feb 17; 296(7):349-53. PubMed ID: 319355
    [Abstract] [Full Text] [Related]

  • 11. Outbreak of amikacin-resistant Enterobacteriaceae in an intensive care nursery.
    Cook LN, Davis RS, Stover BH.
    Pediatrics; 1980 Feb 17; 65(2):264-8. PubMed ID: 6986597
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL, Alvarez S, Ortega G, Verghese A, Holtsclaw-Berk SA.
    Arch Intern Med; 1986 Mar 17; 146(3):538-41. PubMed ID: 3954526
    [Abstract] [Full Text] [Related]

  • 14. Amikacin therapy for severe gram-negative sepsis: efficacy in infections involving gentamicin-resistant organisms.
    Tally FP, Louie TJ, O'Keefe P, Gorbach SL, Bartlett JG.
    J Infect Dis; 1976 Nov 17; 134 SUPPL():S428-32. PubMed ID: 993634
    [Abstract] [Full Text] [Related]

  • 15. Replacement of gentamicin by amikacin as a means of decreasing gentamicin resistance of gram-negative rods in a neonatal intensive care unit.
    Wielunsky E, Drucker M, Cohen T, Reisner SH.
    Isr J Med Sci; 1983 Nov 17; 19(11):1006-8. PubMed ID: 6662682
    [Abstract] [Full Text] [Related]

  • 16. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
    Yetkin G, Otlu B, Cicek A, Kuzucu C, Durmaz R.
    Am J Infect Control; 2006 May 17; 34(4):188-92. PubMed ID: 16679175
    [Abstract] [Full Text] [Related]

  • 17. Experimental infection in rabbits evoked by Pseudomonas aeruginosa, Proteus mirabilis, Escherichia coli and Klebsiella pneumoniae treated with gentamicin, amikacin and sisomicin.
    Jeljaszewicz J, Włodarczak K, Bis W, Kazanowski A, Kuzniewski P, Molska J.
    Zentralbl Bakteriol A; 1980 Aug 17; 247(3):347-52. PubMed ID: 6999802
    [Abstract] [Full Text] [Related]

  • 18. Gentamicin resistance among gram-negative bacillary blood isolates in a hospital with long-term use of gentamicin.
    Mylotte JM.
    Arch Intern Med; 1987 Sep 17; 147(9):1642-4. PubMed ID: 3307673
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Nosocomial consequences of antibiotic usage.
    Giamarellou H, Touliatou K, Koratzanis G, Petrikkos G, Kanellakopoulou K, Lelekis M, Pagona A, Tsagarakis J, Symeonides J, Falagas M.
    Scand J Infect Dis Suppl; 1986 Sep 17; 49():182-8. PubMed ID: 3103210
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.